Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

LY96 antibody

This anti-LY96 antibody is a Mouse Monoclonal antibody detecting LY96 in FACS and InhA. Suitable for Human. This Primary Antibody has been cited in 4+ publications.
Catalog No. ABIN2192085

Quick Overview for LY96 antibody (ABIN2192085)

Target

See all LY96 Antibodies
LY96 (Lymphocyte Antigen 96 (LY96))

Reactivity

  • 48
  • 14
  • 5
  • 2
  • 1
  • 1
  • 1
  • 1
Human

Host

  • 41
  • 13
Mouse

Clonality

  • 44
  • 10
Monoclonal

Conjugate

  • 31
  • 10
  • 3
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
This LY96 antibody is un-conjugated

Application

  • 41
  • 16
  • 14
  • 10
  • 7
  • 6
  • 6
  • 3
  • 3
  • 2
  • 1
  • 1
  • 1
  • 1
Flow Cytometry (FACS), Inhibition Assay (InhA)

Clone

18H10
  • Sterility

    0.2 μm filtered

    Immunogen

    TLR4/MD-2 expressing CHO cells/ chimeric TLR4/MD-2 fusion protein
  • Application Notes

    For flow cytometry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, dilutions have to be made according to the amounts of MD-2 to be inactivated.

    Restrictions

    For Research Use only
  • Buffer

    PBS, containing 0.1 % bovine serum albumin.

    Storage

    4 °C

    Storage Comment

    Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.

    Expiry Date

    12 months
  • Tissières, Dunn-Siegrist, Schäppi, Elson, Comte, Nobre, Pugin: "Soluble MD-2 is an acute-phase protein and an opsonin for Gram-negative bacteria." in: Blood, Vol. 111, Issue 4, pp. 2122-31, (2008) (PubMed).

    Daubeuf, Mathison, Spiller, Hugues, Herren, Ferlin, Kosco-Vilbois, Wagner, Kirschning, Ulevitch, Elson: "TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 179, Issue 9, pp. 6107-14, (2007) (PubMed).

    Elson, Dunn-Siegrist, Daubeuf, Pugin: "Contribution of Toll-like receptors to the innate immune response to Gram-negative and Gram-positive bacteria." in: Blood, Vol. 109, Issue 4, pp. 1574-83, (2007) (PubMed).

    Pugin, Stern-Voeffray, Daubeuf, Matthay, Elson, Dunn-Siegrist: "Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock." in: Blood, Vol. 104, Issue 13, pp. 4071-9, (2004) (PubMed).

  • Target

    LY96 (Lymphocyte Antigen 96 (LY96))

    Alternative Name

    Md-2

    Background

    The monoclonal antibody 18H10 reacts with MD-2, an accessory molecule of the Toll-like receptor 4 (TLR4, CD284). TLRs belong to a family of proteins that specifically recognizes and senses microbial products. They are highly conserved throughout evolution and act as innate immune recognition receptors against many pathogens. TLR4 is a functional receptor for gram-negative bacterial lipopolysaccharides (LPS). TLR4 associates with MD-2 which is absolutely required for LPS-induced activation of TLR4. MD-2 exists as a cell surface protein in association with TLR4. It also exists as secreted forms consisting of MD-2 monomers and multimers (sMD-2). Circulating sMD-2 is mainly present as a doublet of ~20 and 25 kD, representing differentially glycosylated forms. Unlike TLR4, sMD-2 binds directly LPS without the need of soluble CD14 (sCD14). However, LPS-MD-2 interactions are increased when LPS is pretreated with CD14. Only monomeric sMD-2 is biologically active and able to associate with TLR4 and LPS. sMD-2 circulates in plasma of healthy individuals as a non-active, polymeric protein. In septic plasma, the total amount of sMD-2 was strongly elevated and contained both sMD-2 polymers and monomers. Soluble MD-2 is proposed to be an important mediator of organ inflammation during sepsis. During experimental human endotoxemia, the monomeric and total sMD-2 content in plasma increased with the kinetics of an acute phase protein. This parallels enhanced TLR4 costimulatory activity. In vitro studies revealed that sMD-2 release appears to be restricted to endothelial and dendritic cells. The monoclonal antibody 18H10 reacts with MD-2. However, it does not react with sMD-2. In addition, the monoclonal antibody 18H10 is able to inhibit bacterial binding to MD-2. Aliases Lymphocyte antigen 96, ESOP-1, LY96

    Pathways

    TLR Signaling, Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Toll-Like Receptors Cascades
You are here:
Chat with us!